AZRX has been the topic of several other reports. ValuEngine downgraded AzurRx BioPharma from a buy rating to a hold rating in a report on Wednesday, January 2nd. Roth Capital initiated coverage on AzurRx BioPharma in a report on Friday, January 25th. They issued a buy rating and a $10.50 target price on the stock. HC Wainwright set a $8.00 target price on AzurRx BioPharma and gave the stock a buy rating in a report on Friday, November 2nd. Finally, Oppenheimer set a $6.00 target price on AzurRx BioPharma and gave the stock a buy rating in a report on Monday, November 19th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. AzurRx BioPharma presently has an average rating of Buy and an average price target of $7.10.
AzurRx BioPharma stock traded up $0.03 during mid-day trading on Wednesday, hitting $2.04. The company had a trading volume of 16,444 shares, compared to its average volume of 71,402. AzurRx BioPharma has a 12 month low of $1.00 and a 12 month high of $3.75.
In other AzurRx BioPharma news, major shareholder Edmund Burke Jr. Ross purchased 23,848 shares of the firm’s stock in a transaction dated Monday, December 31st. The stock was purchased at an average price of $1.12 per share, for a total transaction of $26,709.76. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Maged Shenouda purchased 20,000 shares of the firm’s stock in a transaction dated Friday, December 28th. The stock was acquired at an average price of $1.31 per share, with a total value of $26,200.00. The disclosure for this purchase can be found here. Insiders bought 186,553 shares of company stock valued at $231,349 in the last 90 days. Company insiders own 7.20% of the company’s stock.
A hedge fund recently raised its stake in AzurRx BioPharma stock. Vanguard Group Inc lifted its holdings in AzurRx BioPharma Inc (NASDAQ:AZRX) by 2.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 413,439 shares of the company’s stock after purchasing an additional 8,489 shares during the quarter. Vanguard Group Inc owned 2.44% of AzurRx BioPharma worth $1,063,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 18.89% of the company’s stock.
About AzurRx BioPharma
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Featured Story: Balance Sheet
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.